Walleye Capital LLC Buys Shares of 106,112 ANI Pharmaceuticals, Inc. $ANIP

Posted by Francis Steltz on Aug 15th, 2026

Walleye Capital LLC bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 106,112 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,784,000. Walleye Capital LLC owned about 0.47% of ANI Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Maryland State Retirement & Pension System increased its position in shares of ANI Pharmaceuticals by 5.4% during the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock valued at $206,000 after purchasing an additional 134 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of ANI Pharmaceuticals by 1.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock worth $736,000 after purchasing an additional 143 shares during the period. CANADA LIFE ASSURANCE Co boosted its holdings in shares of ANI Pharmaceuticals by 1.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after buying an additional 198 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its holdings in shares of ANI Pharmaceuticals by 5.1% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock worth $323,000 after buying an additional 200 shares during the last quarter. Finally, Federation des caisses Desjardins du Quebec boosted its holdings in shares of ANI Pharmaceuticals by 0.6% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock worth $3,110,000 after buying an additional 221 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Stephen P. Carey sold 2,850 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total transaction of $231,876.00. Following the sale, the chief financial officer directly owned 174,693 shares in the company, valued at $14,213,022.48. This trade represents a 1.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the sale, the director owned 38,878 shares in the company, valued at $3,144,452.64. The trade was a 4.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 18,987 shares of company stock valued at $1,546,405. 8.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have commented on ANIP shares. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Guggenheim dropped their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday. Canaccord Genuity Group cut their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $105.83.

Get Our Latest Stock Analysis on ANIP

ANI Pharmaceuticals Trading Up 2.4%

Shares of NASDAQ:ANIP opened at $76.54 on Friday. The stock has a 50 day moving average of $80.82 and a 200 day moving average of $79.03. The company has a market cap of $1.76 billion, a PE ratio of 16.50 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 12-month low of $70.15 and a 12-month high of $99.50. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last released its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. During the same quarter last year, the business earned $1.80 EPS. The firm’s revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.

ANI Pharmaceuticals Company Profile

(Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.